Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 198

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer's disease

De Deyn, Peter Paul, Carrasco, Manuel Martín, Deberdt, Walter, Jeandel, Claude, Hay, Donald P., Feldman, Peter D., Young, Carrie A., Lehman, Deborah L., Breier, Alan · 2004 · International Journal of Geriatric Psychiatry

Abstract

Objectives: Psychotic symptoms and behavioral disturbances are a concern in the care of elderly patients with Alzheimer's dementia (AD). This study was conducted to compare the efficacy of olanzapine versus placebo in patients with psychotic symptoms associated with AD in long‐term or continuing‐care settings. Methods: Patients (n = 652) with AD and delusions or hallucinations were randomly assigned to 10 weeks of double‐blind treatment with placebo or fixed‐dose olanzapine (1.0, 2.5, 5.0, 7.5 mg/day). Results: Mean age was 76.6±10.4 years. Repeated‐measures analysis showed significant improvement from baseline in NPI/NH Psychosis Total scores (sum of Delusions, Hallucinations items—primary efficacy measure) in all five treatment groups (p<0.001), but no pairwise treatment differences were seen at the 10‐week endpoint. However, under LOCF analysis, improvement in the 7.5 mg olanzapine group (−6.2 ± 4.9) was significantly greater than with placebo (−5.0 ± 6.1, p = 0.008), while endpoint CGI‐C scores showed the greatest improvement in the Olz 2.5 olanzapine group (2.8 ± 1.4, p = 0.030) relative to placebo (3.2 ± 1.4). There were significant overall treatment‐group differences in increased weight, anorexia, and urinary incontinence, with olanzapine showing numerically higher incidences. However, neither the incidence of any other individual events, including extrapyramidal symptoms, nor of total adverse events occurred with significantly higher frequency in any olanzapine group relative to placebo. No clinically relevant significant changes were seen across groups in cognition or any other vital sign or laboratory measure, including glucose, triglyceride, and cholesterol. Conclusions: While 1.0 mg olanzapine did not show significant differences from placebo, the 2.5 mg dose was a reasonable starting dose. Olanzapine at 7.5 mg/day significantly decreased psychosis and overall behavioral disturbances (NPI/NH, BPRS) and was well tolerated. Copyright © 2004 John Wiley & Sons, Ltd.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/gps.1032

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

Metadata

Authors
De Deyn, P. P., Carrasco, M. M., Deberdt, W., Jeandel, C., Hay, D. P., Feldman, P. D., Young, C. A., Lehman, D. L., & Breier, A.
Venue
International Journal of Geriatric Psychiatry
Publisher
Wiley
Published
2004-01-28
Volume
19
Issue
2
Pages
115-126
ISSN
  • 0885-6230 (ISSN-L)
  • 1099-1166
OpenAlex
W2112815097
Cited by
198
References
5
FWCI
16.98
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.